HOUSTON--(BUSINESS WIRE)-- CorInnova, an emerging medical device company developing breakthrough technology for the treatment of Heart Failure, announced today that it has been selected to present at the Society for Thoracic Surgeons (STS) / American Association for Thoracic Surgery (AATS) Tech-Con 2018 event to be held this coming Saturday, Jan. 27, in Fort Lauderdale, Fla. STS/AATS Tech-Con is a jointly sponsored program on novel therapies in cardiac and general thoracic surgery, held annually immediately preceding the STS Annual Meeting.

“Being invited to present our technology at Tech-Con is the sixth major honor we have earned over the past five months, and audiences quickly comprehend the dramatic value proposition of EpicHeart as a potentially transformational paradigm for treating Heart Failure,” said William Altman, CEO of CorInnova. “Currently, less than two percent of end-stage Heart Failure patients are treated by transplant or by LVADS. Only about up to eight percent are considered eligible for LVADs due to the invasive surgery required for implantation.

“EpicHeart may potentially quadruple the number of patients who might benefit from a minimally invasive heart assist device,” added Altman. “Like the introduction of pacemakers and ICDs to patients with electrical abnormalities affecting heart function, EpicHeart has the potential to transform the treatment of heart failure patients worldwide.”

Click here to see how CorInnova’s EpicHeart™ soft robotic, non-blood-contacting heart assist device is delivered minimally invasively to support heart function.

Selection to present at Tech-Con is the latest in a string of recent awards and honors won by CorInnova at its last six conferences, including: First Prize Innovation Challenge at RESI (Redefining Early Stage Investments) San Francisco 2018; a 2017 US-China Innovation Alliance InnoSTARS Prize awarded in Kunming, China; a Most Promising Texas Life Science Company Award at the 2017 Texas Life Science Forum; a $50,000 NCC-PDI Pediatric Innovation Prize; and selection as a semi-finalist at the TCT 2017 Shark Tank competition at the world’s largest interventional cardiology conference, TCT 2017.

About CorInnova Inc.
CorInnova has been supported by a group of private investors, a major investment from the UK-based Wellcome Trust (Translation Fund Award No. 104613); federal institutions including the NIH, National Heart Lung Blood Institute (NHLBI), and National Science Foundation (NSF); and the Texas Emerging Technology Fund.

CAUTION: EpicHeart™ is not approved for human use at this time.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180125005736/en/